Ardelyx (ARDX) Competitors

Harmony Biosciences (NASDAQ:HRMY) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings.

Is HRMY or ARDX more profitable?

Harmony Biosciences has a net margin of 22.16% compared to Harmony Biosciences' net margin of -53.08%. Ardelyx's return on equity of 27.49% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	22.16%	27.49%	16.83%
Ardelyx	-53.08%	-43.57%	-26.03%

Do analysts rate HRMY or ARDX?

Harmony Biosciences currently has a consensus target price of $40.63, indicating a potential upside of 38.18%. Ardelyx has a consensus target price of $12.69, indicating a potential upside of 95.79%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ardelyx	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11

Do insiders and institutionals hold more shares of HRMY or ARDX?

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 28.4% of Harmony Biosciences shares are held by insiders. Comparatively, 5.5% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has better valuation & earnings, HRMY or ARDX?

Harmony Biosciences has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$582.02M	2.87	$128.85M	$2.12	13.87
Ardelyx	$124.46M	12.12	-$66.07M	-$0.30	-21.60

Does the MarketBeat Community favor HRMY or ARDX?

Ardelyx received 477 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 67.58% of users gave Ardelyx an outperform vote while only 59.70% of users gave Harmony Biosciences an outperform vote.

Company	Underperform	Outperform
Harmony Biosciences	Outperform Votes 40 59.70%	Underperform Votes 27 40.30%
Ardelyx	Outperform Votes 517 67.58%	Underperform Votes 248 32.42%

Does the media prefer HRMY or ARDX?

In the previous week, Ardelyx had 6 more articles in the media than Harmony Biosciences. MarketBeat recorded 11 mentions for Ardelyx and 5 mentions for Harmony Biosciences. Ardelyx's average media sentiment score of 1.20 beat Harmony Biosciences' score of 0.47 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, HRMY or ARDX?

Harmony Biosciences has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Summary

Harmony Biosciences beats Ardelyx on 10 of the 19 factors compared between the two stocks.